Total Payments
$6,833
2024 Payments
$18.88
Companies
4
Transactions
17
Medicare Patients
6,483
Medicare Billing
$676,297
Payment Breakdown by Category
Consulting$5,500 (80.5%)
Travel$1,003 (14.7%)
Food & Beverage$329.39 (4.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,500 | 2 | 80.5% |
| Travel and Lodging | $1,003 | 3 | 14.7% |
| Food and Beverage | $329.39 | 12 | 4.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $6,774 | 14 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $26.23 | 1 | $0 (2017) |
| GENZYME CORPORATION | $16.38 | 1 | $0 (2017) |
| AbbVie, Inc. | $15.94 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18.88 | 1 | Janssen Biotech, Inc. ($18.88) |
| 2023 | $39.07 | 1 | Janssen Biotech, Inc. ($39.07) |
| 2019 | $15.94 | 1 | AbbVie, Inc. ($15.94) |
| 2017 | $6,759 | 14 | Janssen Biotech, Inc. ($6,716) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Immunology | ||||||
| 10/05/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $39.07 | General |
| Category: Immunology | ||||||
| 05/09/2019 | AbbVie, Inc. | Humira (Biological), Skyrizi | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Immunology | ||||||
| 11/01/2017 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 11/01/2017 | Janssen Biotech, Inc. | — | Travel and Lodging | In-kind items and services | $788.59 | General |
| 11/01/2017 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $49.99 | General |
| 11/01/2017 | Janssen Biotech, Inc. | — | Travel and Lodging | Cash or cash equivalent | $35.00 | General |
| 11/01/2017 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $34.99 | General |
| 11/01/2017 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 08/24/2017 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: Immunology | ||||||
| 05/22/2017 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: DERMATOLOGY | ||||||
| 05/11/2017 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| 05/11/2017 | Janssen Biotech, Inc. | — | Travel and Lodging | In-kind items and services | $179.67 | General |
| 05/11/2017 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $46.49 | General |
| 05/11/2017 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $34.54 | General |
| 05/11/2017 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $14.94 | General |
| 04/24/2017 | GENZYME CORPORATION | DUPIXENT (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,617 | 3,212 | $540,725 | $154,586 |
| 2022 | 23 | 1,773 | 3,603 | $604,795 | $177,059 |
| 2021 | 24 | 1,825 | 3,600 | $738,800 | $214,560 |
| 2020 | 25 | 1,268 | 2,312 | $464,670 | $130,091 |
Total Patients
6,483
Total Services
12,727
Medicare Billing
$676,297
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 334 | 425 | $85,000 | $30,524 | 35.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 128 | 151 | $49,075 | $15,499 | 31.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 279 | 382 | $66,850 | $15,021 | 22.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 146 | 163 | $52,975 | $13,740 | 25.9% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 56 | 90 | $36,000 | $11,740 | 32.6% |
| 67850 | Destruction of growth of eyelid margin, 1.0 cm or less | Office | 2023 | 57 | 74 | $35,150 | $10,632 | 30.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 163 | 227 | $28,375 | $10,528 | 37.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 205 | 1,360 | $40,800 | $7,861 | 19.3% |
| 17283 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 2.1-3.0 cm | Office | 2023 | 30 | 38 | $26,600 | $6,565 | 24.7% |
| 17284 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 3.1-4.0 cm | Office | 2023 | 23 | 29 | $23,200 | $5,924 | 25.5% |
| 11606 | Removal of cancer skin growth of body, arms, or legs, more than 4.0 cm | Office | 2023 | 12 | 15 | $16,500 | $5,831 | 35.3% |
| 17264 | Destruction of cancer skin growth of trunk, arms, or legs, 3.1-4.0 cm | Office | 2023 | 14 | 20 | $13,000 | $3,120 | 24.0% |
| 17274 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 3.1-4.0 cm | Office | 2023 | 14 | 16 | $12,000 | $3,027 | 25.2% |
| 17276 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, more than 4.0 cm | Office | 2023 | 11 | 13 | $8,450 | $2,773 | 32.8% |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | Office | 2023 | 20 | 21 | $10,500 | $2,632 | 25.1% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 45 | 45 | $7,875 | $2,592 | 32.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 26 | 26 | $6,760 | $2,257 | 33.4% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 13 | 15 | $9,000 | $1,956 | 21.7% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 16 | 19 | $8,075 | $1,335 | 16.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 13 | 14 | $3,850 | $972.67 | 25.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 12 | 69 | $690.00 | $56.94 | 8.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 291 | 375 | $75,000 | $28,173 | 37.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 172 | 207 | $67,275 | $16,514 | 24.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 282 | 390 | $68,250 | $16,206 | 23.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 230 | 315 | $39,375 | $14,935 | 37.9% |
About Dr. Jonathan Held, M.D
Dr. Jonathan Held, M.D is a Specialist healthcare provider based in Ayer, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1699767608.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Held, M.D has received a total of $6,833 in payments from pharmaceutical and medical device companies, with $18.88 received in 2024. These payments were reported across 17 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($5,500).
As a Medicare-enrolled provider, Held has provided services to 6,483 Medicare beneficiaries, totaling 12,727 services with total Medicare billing of $676,297. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Ayer, MA
- Active Since 08/16/2005
- Last Updated 07/08/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1699767608
Products in Payments
- TREMFYA (Drug) $57.95
- COSENTYX (Biological) $26.23
- STELARA (Biological) $16.94
- DUPIXENT (Drug) $16.38
- Humira (Biological) $15.94
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.